Should we regard CA125 as the indication to treat relapsing ovarian cancer?
Fisken
J
J
Leonard
R C
RC
Roulston
J E
JE
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D005260:Female; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000276:immunology* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000628:therapy
D015295:Antigens, Tumor-Associated, Carbohydrate